Genentech Girds For Competition From Generics And Big Pharma
Executive Summary
Genentech will develop a defensive plan for each of its products in preparation for the potential introduction of follow-on biologics, Exec VP-Commercial Operations Ian Clark said during an investor update meeting March 17